National Pension Service increased its position in shares of Boston Scientific Corp. (NYSE:BSX) by 8.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 977,146 shares of the company’s stock after buying an additional 77,539 shares during the period. National Pension Service owned approximately 0.07% of Boston Scientific Corp. worth $23,256,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in BSX. First Republic Investment Management Inc. increased its stake in shares of Boston Scientific Corp. by 71.1% in the first quarter. First Republic Investment Management Inc. now owns 294,625 shares of the company’s stock worth $5,541,000 after buying an additional 122,466 shares during the period. DNB Asset Management AS increased its stake in shares of Boston Scientific Corp. by 3.7% in the second quarter. DNB Asset Management AS now owns 109,350 shares of the company’s stock worth $2,556,000 after buying an additional 3,900 shares during the period. Exxonmobil Investment Management Inc. TX increased its stake in shares of Boston Scientific Corp. by 7.0% in the second quarter. Exxonmobil Investment Management Inc. TX now owns 351,225 shares of the company’s stock worth $8,208,000 after buying an additional 22,936 shares during the period. Chevy Chase Trust Holdings Inc. increased its stake in shares of Boston Scientific Corp. by 1.8% in the second quarter. Chevy Chase Trust Holdings Inc. now owns 1,160,528 shares of the company’s stock worth $27,122,000 after buying an additional 19,969 shares during the period. Finally, NN Investment Partners Holdings N.V. increased its stake in shares of Boston Scientific Corp. by 11.6% in the second quarter. NN Investment Partners Holdings N.V. now owns 8,634 shares of the company’s stock worth $202,000 after buying an additional 900 shares during the period. Institutional investors own 89.96% of the company’s stock.

Institutional Ownership by Quarter for Boston Scientific Corp. (NYSE:BSX)

Shares of Boston Scientific Corp. (NYSE:BSX) traded down 1.20% on Wednesday, reaching $20.52. 1,439,943 shares of the company’s stock were exchanged. The company has a market cap of $27.94 billion, a price-to-earnings ratio of 387.17 and a beta of 1.15. Boston Scientific Corp. has a 12 month low of $15.67 and a 12 month high of $24.79. The firm’s 50-day moving average price is $22.04 and its 200 day moving average price is $23.09.

Boston Scientific Corp. (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 26th. The company reported $0.27 earnings per share for the quarter, hitting the consensus estimate of $0.27. The company had revenue of $2.11 billion for the quarter, compared to analyst estimates of $2.07 billion. Boston Scientific Corp. had a net margin of 0.99% and a return on equity of 23.25%. Boston Scientific Corp.’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.24 EPS. Equities research analysts predict that Boston Scientific Corp. will post $1.10 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this story on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2016/11/30/national-pension-service-increases-position-in-boston-scientific-corp-bsx.html.

A number of equities research analysts have recently commented on BSX shares. Citigroup Inc. increased their price objective on Boston Scientific Corp. from $26.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, August 3rd. Zacks Investment Research lowered Boston Scientific Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, August 31st. Argus upgraded Boston Scientific Corp. from a “hold” rating to a “buy” rating and increased their target price for the company from $23.82 to $33.00 in a report on Thursday, September 1st. They noted that the move was a valuation call. Royal Bank Of Canada restated an “outperform” rating and issued a $28.00 target price on shares of Boston Scientific Corp. in a report on Friday, October 14th. Finally, TheStreet upgraded Boston Scientific Corp. from a “hold” rating to a “buy” rating in a report on Wednesday, October 26th. Five investment analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company’s stock. Boston Scientific Corp. currently has a consensus rating of “Buy” and an average target price of $25.70.

About Boston Scientific Corp.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

5 Day Chart for NYSE:BSX

Receive News & Stock Ratings for Boston Scientific Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corp. and related stocks with our FREE daily email newsletter.